Skip to Main Content

Clinical Studies and Protocols

Site Map Investigators Log-in
(PHO-0956) Fructose study

 Return to List of Clinical Studies
 Return to List of Protocols for Obesity, Metabolism and Weight Loss
Effects of dietary fructose on gut microbiota and fecal metabolites in obese men and postmenopausal women: A pilot study

Principal Investigator:
Peter R. Holt M.D.


Contact Information:
Clinical Research Support Office
1230 York Avenue
New York, NY 10065
Telephone: 212-327-7722
Enrollment Status:

Brief Summary of Protocol:
Foods and beverages in the U.S. are typically sweetened with sucrose (50% glucose and 50% fructose) or high fructose corn syrup (45-58% glucose and 42-55% fructose). Dietary fructose has been suggested to play a role in the development of obesity, non-alcoholic fatty liver disease (NAFLD), diabetes, and cardiovascular disease and it has been found to alter the gut bacteria in animals. There is evidence that gut bacteria contribute to a range of human diseases including those of the liver and digestive tract. This research will explore the effect dietary fructose may play on gut bacteria and the products that these bacteria make, in humans, and the development of chronic health conditions.

Detailed Description of Protocol:
This study involves at least two outpatient screening visits to determine your eligibility, followed by two 16 to 18 day inpatient stays after with a two week wash-out period at home between the inpatient stays. We are asking you to take part in this research study because you are a healthy overweight man or postmenopausal woman.

What specifically makes a person eligible for the study?
You may be eligible to enter this study:

- Are between 45 and 70 years old
- Overweight (BMI between 30 and 39.9)
- In good general health



Children permitted to participate:

Potential Benefits.....
There are no direct benefits to you. The information gained from this research study may benefit people who have NAFLD in the future.

Compensation is provided.